Viewing data from:

PARICALCITOL

ANDA

PARICALCITOL | A203897 | RISING PHARMA HOLDINGS INC

3 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: ZEMPLAR

Hatch-Waxman Litigation

1 case on OB patents from PACER

Case	Court	Filed	Status	Judge
Abbott Laboratories et al v. Agila Specialties Private Limited et al 1:2012cv00520 3 patentsANDA 203897paricalcitol	D. Del.	2012-04-25	Terminated 2012-08-22	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

API Supply Chain10 active DMFs

10 active API suppliers hold Drug Master Files for this ingredient.

SAFC INCPARICALCITOL

DMF 113401995

TAPI NL BVPARICALCITOL USP

DMF 208652007

ALP PHARM BEIJING CO LTDPARICALCITOL USP (NON-STERILE DRUG SUBSTANCE)

DMF 212552008

FORMOSA LABORATORIES INCPARICALCITOL

DMF 218802008

NEULAND LABORATORIES LTDPARICALCITOL USP

DMF 238952010

ABBVIE INCPARICALCITOL DRUG SUBSTANCE

DMF 243152010

DISHMAN NETHERLANDS BVPARICALCITOL

DMF 253002011

SAI LIFE SCIENCES LTDPARICALCITOL USP, NON-STERILE BULK DRUG

DMF 265452012

CHONGQING HUAPONT PHARMACEUTICAL CO LTDPARICALCITOL

DMF 285502014

NANJING HERON PHARMACEUTICAL CO LTDPARICALCITOL

DMF 382692023

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (3)

Sort:

#001 — 0.002MG/ML (0.002MG/ML)

0 patents0 exclusivities▴

SOLUTION;INTRAVENOUS | Approved: Nov 2, 2017

No patent or exclusivity listings for this strength.

#002 — 0.005MG/ML (0.005MG/ML)

0 patents0 exclusivities▾

SOLUTION;INTRAVENOUS | Approved: Nov 2, 2017

#003 — 0.01MG/2ML (0.005MG/ML)

0 patents0 exclusivities▾

SOLUTION;INTRAVENOUS | Approved: Nov 2, 2017